ADMA, SDMA and L-arginine may be Novel Targets in Pharmacotherapy for Complications due to Cardiopulmonary Bypass
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Biochemistry"
DOI: 10.1515/jomb-2016-0025
Abstract: Summary Background: In this study, the effects of olmesartan therapy on asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), L-arginine and inducible nitric oxide synthase (iNOS) levels were investigated in patients undergoing cardiopulmonary bypass. Methods: Patients were… read more here.
Keywords: bypass; sdma arginine; group; time ... See more keywords
Asymmetric Dimethylarginine in an NMU-induced Rat Mammary Tumor Model
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.16138
Abstract: Background/Aim: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) production and a newly discovered risk factor involved in endothelial dysfunction and adverse cardiovascular events. Recently, both NO and ADMA have also emerged… read more here.
Keywords: dimethylarginine; asymmetric dimethylarginine; dimethylarginine nmu; sdma arginine ... See more keywords